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OBJECTIVE—We prospectively investigated in hypertensive patients with type 2 diabetes if
bedtime treatment with $1 hypertension medications exerts better blood pressure control and
cardiovascularriskreductionthanconventionaltherapy,inwhichallmedicationsareingestedin
the morning.
RESEARCH DESIGN AND METHODS—We conducted a prospective, randomized,
open-label, blinded end point trial on 448 hypertensive patients with type 2 diabetes, 255
men/193 women, mean 6 SD age 62.5 6 10.8 years, randomized to ingest all their prescribed
hypertension medications upon awakening or $1 of them at bedtime. Ambulatory blood pres-
sure was measured for 48 h at baseline and again annually or even more frequently (quarterly)
after adjustments in treatment.
RESULTS—After a median follow-up of 5.4 years, patients ingesting $1 hypertension med-
ications at bedtime showed a signiﬁcantly lower cardiovascular risk (adjusted by age and sex)
than subjects ingesting all medications upon awakening (hazard ratio 0.33 [95% CI 0.21–0.54];
P , 0.001). The difference between groups in the adjusted risk of major events (cardiovascular
death, myocardial infarction, and stroke) was also statistically signiﬁcant (0.25 [0.10–0.61]; P =
0.003). Patients treated at bedtime showed signiﬁcantly lower sleep time blood pressure mean
and higher prevalence of controlled ambulatory blood pressure (62.5 vs. 50.9%; P =0 . 0 1 3 ) .
There was a signiﬁcant 12% cardiovascular risk reduction per each 5 mmHg decrease in asleep
systolic blood pressure during follow-up (P , 0.001).
CONCLUSIONS—Among patients with diabetes, treatment with $1 hypertension medica-
tions at bedtime,compared with allmedicationsupon waking,resulted in improved ambulatory
blood pressure control and signiﬁcantly reduced cardiovascular morbidity and mortality.
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A
number of published prospective
trials reviewed elsewhere (1) have
reported clinically meaningful
morning/evening treatment time differ-
ences in blood pressure lowering efﬁcacy,
duration of action, safety proﬁle, and/or
effects on the circadian blood pressure
pattern for different classes of hyperten-
sion medications. For instance, a once-
dailyevening,incomparisonwithmorning,
ingestion schedule of angiotensin receptor
blockers(ARBs)andangiotensin-converting
enzyme inhibitors (ACEIs) results in
greater therapeutic effect on asleep blood
pressure, independent of the terminal
half-lifeofeachindividualmedication(1).
The impact of bedtime chronotherapy
on sleep time blood pressure regulation
might be of clinical importance. This per-
spectiveisbasedonthegrowingnumberof
studies, all concerning ambulatory blood
pressure monitoring (ABPM), that have
consistently shown an association between
blunted sleep time blood pressure decline
and increased incidence of cardiovas-
cular disease (CVD) events, both in sub-
jects without (2–4) as well as with diabetes
(5–7). Independent prospective studies
have also found that the sleep time blood
pressure mean is a better predictor of CVD
risk than the daytime or 24-h blood pres-
suremean(3,8–12),arelevantﬁndingalso
documented for patients with diabetes
(13–15). Nocturnal hypertension is not
onlyfrequentbutalsohighlypredominant
in patients with diabetes (6,7,13–15). A
limitation of all of these previous studies
ontheprognosticvalueofnighttimeblood
pressure is their reliance on a single base-
line ABPM proﬁle from each participant at
the time of inclusion, without accounting
for changes in the blood pressure pattern
or level during the years of follow-up.
Thus, the potential reduction in CVD
risk associated with speciﬁcally reducing
sleeptime blood pressure,whichhasbeen
found to be much more feasible by bed-
time than by upon waking dosing of con-
ventionalhypertensionmedications (1),is
still a matter of debate.
The MAPEC (Monitorización Ambu-
latoria para Predicción de Eventos Cardio-
vasculares [Ambulatory Blood Pressure
Monitoring for Prediction of Cardiovas-
cular Events]) study was speciﬁcally
designed to investigate prospectively
whether bedtime treatment with $1h y -
pertension medications exerts signiﬁ-
cantly better blood pressure control and
CVD risk reduction than conventional
therapy, in which all medications are in-
gested upon waking (16,17). We here re-
port results on the differential effect of
blood pressure–lowering chronotherapy
on CVD risk in hypertensive patients
with type 2 diabetes.
RESEARCH DESIGN AND
METHODS
Inclusion and exclusion criteria
An extended version of the methods is
available in the Supplementary Data. In
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ORIGINAL ARTICLEsummary, the sample represents a pop-
ulation of Spanish hypertensive patients
with type 2 diabetes of both sexes and
$18 years of age. Exclusion criteria were
pregnancy,history ofdrug/alcoholabuse,
night/shift work employment, diagnosis
of AIDS, type 1 diabetes, secondary hy-
pertension,CVDdisorders(unstableangina
pectoris, heart failure, life-threatening ar-
rhythmia, nephropathy, and grade III-IV
retinopathy), intolerance to ABPM, and
inability to communicate and comply
withallstudyrequirements.Thisprospec-
tive single-center study (registered at
www.clinicaltrials.gov, NCT00295542)
wasapprovedbythestateEthicsCommittee
of Clinical Research. All patients gave
w r i t t e ni n f o r m e dc o n s e n t .
Subjects and diagnostic criteria
We assessed 480 patients fulﬁlling the
inclusion/exclusion criteria. Among these,
448 (255 men/193 women, mean 6 SD
62.5 6 10.8 years of age) provided all re-
quired information for the study. We
established a priori a minimum time of
follow-up of $6 months for each patient
and a minimum median follow-up of 5
years (16). A total of 32 patients evaluated
by ABPM for potential inclusion were not
randomizedasaresultoftheirlackofcon-
sent for additional ABPM evaluations. Di-
agnosis of hypertension was based on
accepted ABPM criteria—an awake blood
pressuremeanof$135/85mmHgforsys-
tolic(SBP)/diastolicbloodpressure(DBP),
or an asleep blood pressure mean $120/
70 mmHg (18).
Study design
This was a prospective, randomized,
open-label, blinded end point trial. Par-
ticipants were randomized to ingest all
their prescribed blood pressure–lowering
medications upon awakening (232 pa-
tients) or $1 of them at bedtime (216
patients). Blood samples were obtained
between 08:00 and 09:00 h, after over-
night fasting, the same week when each
48-h ABPM session was initiated. Just be-
fore commencing ABPM, six clinic blood
pressure measurements were obtained
with a validated automatic oscillometric
device (HEM-705IT; Omron Health
Care, Vernon Hills, IL) after the patient
had rested in a seated position for $10
min.
ABPM assessment
At inclusion, as well as at each scheduled
visit for ABPM during follow-up (see be-
low), the SBP and DBP of each patient
were automatically measured every20min
between 07:00 and 23:00 h and every 30
min during the night for 48 consecutive
hours with a calibrated SpaceLabs 90207
ABPM monitor (SpaceLabs, Issaquah,
WA). Blood pressure series were consid-
ered invalid for analysis if $30% of the
measurements were missing, if data were
lackingforanintervalof.2h,ifdatawere
obtained while patients had an irregular
rest-activity schedule during the two
days of monitoring, or if the nighttime
s l e e pp e r i o dw a s,6o r.12 h during
ABPM.
Actigraphy
All patients wore an actigraph (Mini-
Motion-Logger; Ambulatory Monitoring,
Ardsley, NY) on the dominant wrist to
monitor physical activity every minute
during ABPM. The actigraphy data, com-
bined with patient diaries, were used to
corroborate the absence of daytime nap-
ping and to deﬁne the commencement
andterminationofthedaytimeawakeand
nocturnal asleep spans so the respective
blood pressure means for each subject
could be accurately determined.
Follow-up
The same evaluation procedure described
above, including conventional clinic blood
pressure measurement, 48-h ABPM and
wrist activity monitoring, and blood sam-
pling, was scheduled annually or more
frequently (after 3 months of any change
in treatment) if the therapeutic scheme
wasmodiﬁedtoimproveambulatoryblood
pressure control. Investigators blinded to
the timed-treatment scheme of each par-
ticipant (thus excluding those performing
clinic evaluation at each visit to the hos-
pital, clinic and ambulatory blood pres-
sure measurement, and/or statistical
analyses) reviewed at least annually the
complete clinical records of all enrolled
patients to assess CVD morbidity and
mortality.Registeredeventsincludeddeath
from all causes, myocardial infarction,
angina pectoris, coronary revasculariza-
tion, heart failure, acute arterial occlusion
of lower extremities, thrombotic occlusion
of the retinal artery, hemorrhagic stroke,
ischemic stroke, and transient ischemic
attack.
Statistical methods
To correct for measurement errors and
outliers, ABPM proﬁles were edited ac-
cording to conventional criteria. Thus,
SBP readings .250 or ,70 mmHg, DBP
.150 or ,40 mmHg, and pulse pressure
(differencebetweenSBPandDBP).150or
,20mmHg were automatically discarded.
The primary outcomes study end points
were total CVD morbidity and mortality,
which included allthe events listed above,
andmajorCVDevents,i.e.,acompositeof
CVD deaths, myocardial infarction, and
stroke. Demographic and clinical charac-
teristics were compared on an intention-
to-treat basis among groups of subjects
randomized to the two treatment time
groups by t test (quantitative variables)
or nonparametric x
2 test (proportions).
The Cox proportional-hazard model was
used to estimate hazard ratios (95% CIs)
for events associated with time of treat-
ment, withadjustmentfor signiﬁcant con-
founding variables. Event rates for fatal
and nonfatal CVD events during follow-up
were also expressed as the number/1,000
patient-years, i.e., ratio of the observed
number of events to the total number of
patient-years of exposure. Survival curves
were generated using the Kaplan-Meier
product-limit method and compared by
the Mantel log-rank test.
RESULTS
Demographic characteristics,
laboratory variables, and
ambulatory blood pressure
At baseline, the two treatment time
groups were comparable for the preva-
lence of obstructive sleep apnea, meta-
bolic syndrome, microalbuminuria, and
obesity, plus all anthropometric variables
andclinicallaboratorytestvalues(Table1).
The clinic blood pressure, mean ambula-
torybloodpressurevalues,andprevalence
of nondipping at baseline were also com-
parable between groups (Table 1).
T h e r ew e r en od i f f e r e n c e si nt h e
classes and number of hypertension med-
ications used for therapy between the two
treatment groups (Table 2). The percent-
ageofpatientstreatedwithstatins(40.5%
inthemorningtreatmentgroup,46.3%in
the evening treatment group; P =0 . 2 1 7
between groups) or low-dose (100 mg/day)
aspirin (22.4 vs. 22.7%; P =0 . 9 4 5 )
were also similar in both treatment time
groups.
The data of the last evaluation re-
vealed differences between the two treat-
ment time groups, signiﬁcant even after
correction for multipletesting. The group
of patients ingesting $1 medications at
bedtime showed signiﬁcantly lower
mean asleep blood pressure than the
group of patients ingesting all their
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Table 2). Differences between groups in
clinic and awake blood pressure were
small and nonsigniﬁcant. The sleep time
relative bloodpressure declinewas signif-
icantly greater among patients ingesting
$1 medications at bedtime; accordingly,
the proportion of patients in this treat-
ment time group with a nondipper blood
pressure proﬁle (sleep time SBP decline
,10%) was signiﬁcantly lower than that
in the upon-awakening treatment time
group (49.5 vs. 76.3%; P , 0.001). Fi-
nally, the proportion of participants with
controlled blood pressure, with reference
to established ABPM criteria for both
awake and asleep blood pressure mean,
was signiﬁcantly greater among patients
ingesting $1 medications at bedtime
than in those ingesting all medications
upon awakening (62.5 vs. 50.9%; P =
0.013; Table 2). This difference in ambu-
latory blood pressure control was mainly
due to improved sleep time blood pres-
sure control in subjects ingesting medica-
tion at bedtime. Thus, although the
percentage of subjects with controlled
awake blood pressure mean was similar
for both treatment time groups (P =
0.439), asleep blood pressure mean was
controlled in a signiﬁcantly larger per-
centage of patients treated at bedtime
(70.8 vs. 54.7%; P , 0.001, Table 2).
CVD risk according to time of day
of hypertension treatment
During the median follow-up period of
5.4 years (range 0.5–8.4), we documented
91 events (11 deaths, 14 myocardial in-
farctions, 8 angina pectoris, 6 coronary
revascularizations, 9 cerebrovascular
events,24heartfailures,7casesofaortoiliac
occlusive disease, and 12 thrombotic oc-
clusions of the retinal artery; Table 2).
Figure 1 (top)p r e s e n t s ,f o rt h et o t a lo f
all the documented events, the Kaplan-
Meier survival curves for the subjects of
the two treatment time groups; a highly
signiﬁcant difference was detected in
event-free survival (log-rank 23.5; P ,
0.001). Table 2 provides further infor-
mation on the distribution of the CVD
events in both treatment time groups. The
bedtime group showed a signiﬁcantly
lower incidence of total and major CVD
events. CVD mortality was more prevalent
among patients who ingested all their
hypertension medications upon awakening
(P = 0.038).
Figure1(bottom)alsoshowsthehazard
ratios of CVD events estimated by the
Cox proportional-hazard model for the
Table 1—Baseline characteristics of patients investigated according to treatment time
(either all hypertension medications upon awakening or ‡1 medications at bedtime)
Awakening Bedtime
P between
groups
Demographic characteristics
n 232 216
Sex (% men) 59.1 54.6 0.345
Obstructive sleep apnea (%) 13.4 11.6 0.568
Metabolic syndrome (%) 86.6 86.6 0.984
Cigarette smoking (%) 8.6 7.9 0.773
Obesity (%) 66.8 64.8 0.656
Microalbuminuria (%) 28.0 26.9 0.782
Previous CVD events (%) 8.2 9.3 0.688
Duration of known diabetes (years) 8.9 6 8.4 8.7 6 8.0 0.804
Duration of known hypertension (years) 7.4 6 8.2 7.6 6 8.7 0.674
Anthropometric variables and clinic blood pressure
Age (years) 62.5 6 10.9 62.5 6 10.7 0.935
Height (cm) 160.6 6 9.2 159.3 6 9.0 0.117
Weight (kg) 83.5 6 16.9 81.1 6 16.0 0.124
BMI (kg/m
2) 32.1 6 5.5 31.9 6 5.2 0.631
Waist circumference (cm) 102.9 6 13.9 102.0 6 11.6 0.442
Clinic SBP (mmHg)† 158.1 6 24.7 161.9 6 22.2 0.085
Clinic DBP (mmHg)† 85.7 6 13.6 87.0 6 12.3 0.303
Clinic PP (mmHg)† 72.4 6 16.9 74.9 6 17.8 0.117
Clinic HR (bpm)† 75.6 6 10.5 76.6 6 13.7 0.391
Clinical laboratory test values
HbA1c (%) 6.9 6 1.7 6.8 6 1.7 0.627
Glucose (mg/dL) 157.2 6 49.1 150.8 6 51.2 0.178
Creatinine (mg/dL) 1.03 6 0.25 1.01 6 0.27 0.393
Uric acid (mg/dL) 6.1 6 2.0 6.0 6 1.6 0.271
Total cholesterol (mg/dL) 203.3 6 45.7 202.7 6 42.0 0.886
Triglycerides (mg/dL) 126.9 6 63.2 120.6 6 68.3 0.321
HDL cholesterol (mg/dL) 44.3 6 13.6 46.6 6 15.2 0.092
LDL cholesterol (mg/dL) 134.9 6 38.1 131.7 6 35.5 0.378
Fibrinogen (mg/dL) 357.7 6 78.1 346.8 6 88.3 0.265
Erythrocyte sedimentation rate (mm) 19.1 6 16.8 17.6 6 15.4 0.349
Glomerular ﬁltration rate‡ 71.0 6 18.2 72.7 6 17.1 0.206
Ambulatory blood pressure
Duration of nocturnal rest (h) 9.2 6 1.3 9.2 6 1.2 0.902
Awake SBP mean (mmHg) 135.4 6 17.9 135.9 6 15.8 0.762
Asleep SBP mean (mmHg) 128.5 6 21.7 129.2 6 20.2 0.702
48-h SBP mean (mmHg) 133.2 6 18.6 133.5 6 16.5 0.837
Sleep time relative SBP decline (%) 5.2 6 8.3 5.0 6 8.7 0.779
Awake DBP mean (mmHg) 76.7 6 11.0 77.3 6 11.0 0.553
Asleep DBP mean (mmHg) 68.3 6 11.4 69.3 6 10.9 0.346
48-h DBP mean (mmHg) 73.9 6 10.8 74.6 6 10.6 0.538
Sleep time relative DBP decline (%) 10.7 6 8.7 10.1 6 8.9 0.432
Nondipper (%) 72.4 70.0 0.558
Data are means 6 SD unless otherwise indicated. Metabolic syndrome is determined by the National Cho-
lesterolEducationProgramAdultTreatmentPanelIII(ATP-III)reviseddeﬁnition(19).Thesleeptimerelative
blood pressure decline, an index of blood pressure dipping, is deﬁned as the percent decline in mean blood
pressureduringnocturnalsleeprelativetothemeanbloodpressureduringdaytimeactivity,andcalculatedas
[(awake blood pressure mean – asleep blood pressure mean)/awake blood pressure mean] 3 100. HR, heart
rate; Nondipper, patients with sleep time relative SBP decline ,10% using data sampled by ABPM for 48
consecutive hours; obesity, BMI $30 kg/m
2; PP, pulse pressure. †Values correspond to the average of six
conventional blood pressure measurements obtained for each subject at the clinic before starting ABPM.
‡Glomerularﬁltrationrate(mL/min/1.73m
2)wasestimatedusingtheChronicKidneyDiseaseEpidemiology
Collaboration equation (20).
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time groups. Adjustments were applied
for sex and age in all comparisons, as
these inﬂuential factors were the only
ones among all the demographic and lab-
oratory variables shown in Table 1 that
were consistently signiﬁcant in all tested
Cox regression models. Patients ingesting
$1 blood pressure–lowering medications
at bedtime evidenced a signiﬁcantly lower
risk of total events than patients ingesting
all of their medications upon awakening
(hazard ratio 0.33 [95% CI 0.21–0.54];
P,0.001).Particularlyrelevantisthedif-
ference between the two treatment time
groups in the risk of major CVD events,
i.e., CVD deaths, myocardial infarction,
and stroke (0.25 [0.10–0.61]; P =0 . 0 0 3 ) .
Results remained unchanged after correc-
tion by the use of statins and/or aspirin,
as these variables were not signiﬁcantly
associated with event-free survival.
Changes in clinic and ambulatory
blood pressure during follow-up
as predictors of CVD risk
The results shown in Table2 indicate that
those patients randomized to ingest $1
medications at bedtime experienced sig-
niﬁcantly better nighttime blood pressure
control as expressed by the enhanced re-
duction of the sleep time blood pressure
mean and increased sleep time relative
blood pressure decline toward a more
dipping blood pressure pattern. More-
over, only 23% of the patients who
experienced a CVD event had their asleep
blood pressure properly controlled
(,120/70 for SBP/DBP); awake blood
pressure, however, was controlled in
43% of event subjects. Accordingly, we
further evaluated the inﬂuence on CVD
risk of changes in ambulatory blood pres-
sure during follow-up. Cox regression
analyses, adjusted for sex, age, and change
in 48-h blood pressure between the ﬁrst
and last evaluations of each patients, re-
vealed that the progressive decrease
in asleep blood pressure mean during
follow-upwasmostsigniﬁcantlyassociated
with event-free survival (12 and 23% risk
reduction for every 5 mmHg decrease in
asleep blood pressure mean of SBP and
DBP, respectively; P , 0.001).
The top panel in Fig. 2 shows, for the
studied population divided in quintiles,
the signiﬁcant relationship between pro-
gressively lower achieved asleep SBP
mean and reduced CVD risk. Adjusted
risk was signiﬁcantly higher (P , 0.001)
in the last three quintiles compared with
the ﬁrst two. There was a progressive
Table 2—Final characteristics of patients investigated according to treatment time
(either all hypertension medications upon awakening or ‡1 medications at bedtime)
Awakening Bedtime
P between
groups
n 232 216
Primary end points*
Total events 54.24 (68) 19.80 (23) ,0.001
Major events 17.55 (22) 5.16 (6) ,0.001
Secondary end points*
Total death 6.38 (8) 2.58 (3) 0.097
Cardiovascular death 4.79 (6) 0.86 (1) 0.038
Other cause 1.60 (2) 1.72 (2) 0.968
Cardiovascular events 15.95 (20) 6.89 (8) 0.008
Cerebrovascular events 6.38 (8) 0.86 (1) 0.010
Heart failure 13.56 (17) 6.02 (7) 0.020
Other events 11.96 (15) 3.44 (4) 0.005
Hypertension treatment
Number of medications 2.6 6 1.1 2.4 6 1.2 0.145
1 Medication (%) 23.7 28.7 0.229
2 Medications (%) 15.9 19.4 0.332
$3 Medications (%) 60.3 51.9 0.070
ARB (%) 63.4 67.1 0.403
ACEI (%) 27.2 20.4 0.159
Calcium channel blocker (%) 50.0 49.1 0.845
a-Blocker (%) 29.7 28.7 0.809
b-Blocker (%) 21.1 22.2 0.777
Diuretic (%) 63.4 56.5 0.137
Clinic and ambulatory blood pressure
Clinic SBP (mmHg)† 150.3 6 28.6 147.9 6 21.3 0.309
Clinic DBP (mmHg)† 80.5 6 16.3 78.6 6 14.3 0.187
Clinic PP (mmHg)† 69.8 6 18.2 69.3 6 14.7 0.742
Clinic HR (bpm)† 73.6 6 13.8 74.6 6 14.2 0.453
Awake SBP mean (mmHg) 127.1 6 17.8 126.8 6 14.6 0.861
Asleep SBP mean (mmHg) 122.4 6 21.8 115.0 6 17.1 ,0.001
48-h SBP mean (mmHg) 125.5 6 18.3 122.8 6 15.0 0.097
Sleep time relative SBP decline (%) 3.7 6 10.3 9.4 6 7.8 ,0.001
Awake DBP mean (mmHg) 70.5 6 10.8 71.0 6 10.7 0.621
Asleep DBP mean (mmHg) 63.7 6 11.3 60.2 6 10.1 ,0.001
48-h DBP mean (mmHg) 68.2 6 10.4 67.4 6 10.1 0.406
Sleep time relative DBP decline (%) 9.3 6 11.4 14.9 6 9.2 ,0.001
Nondipper (%) 76.3 49.5 ,0.001
Controlled ambulatory blood pressure (%) 50.9 62.5 0.013
Controlled awake blood pressure (%) 75.4 72.2 0.439
Controlled asleep blood pressure (%) 54.7 70.8 ,0.001
Dataaremeans6SD.Eventrates(95%CIs)areexpressedasthenumber/1,000patient-years,i.e.,ratioofthe
observednumberofeventstothetotalnumberofpatient-yearsofexposure.Totaleventsincludedeath(from
all causes), cardiovascular events (myocardial infarction, angina pectoris, and coronary revascularization),
cerebrovascular events (stroke and transient ischemic attack), heart failure, and other events (acute arterial
occlusion of lower extremities and thrombotic occlusion of the retinal artery). Major events include car-
diovascular deaths, myocardial infarction, ischemic stroke, and hemorrhagic stroke. Comparison of event
rates between treatment time groups was done by the Mantel log-rank test. The sleep time relative blood
pressuredecline,anindexofbloodpressuredipping,isdeﬁnedasthepercentdeclineinmeanbloodpressure
duringnocturnalsleeprelativetothemeanbloodpressureduringdaytimeactivity,andcalculatedas:[(awake
blood pressure mean – asleep blood pressure mean)/awake blood pressure mean] x 100. HR, heart rate;
Nondipper, patients with sleep time relative SBP decline ,10% using data sampled by ABPM for 48 con-
secutive hours; PP, pulse pressure. *Number of events is shown in parentheses. †Values correspond to the
average of six conventional blood pressure measurements obtained for each subject at the clinic before
starting ABPM.
care.diabetesjournals.org DIABETES CARE, VOLUME 34, JUNE 2011 1273
Hermida and Associatesreduction from 65 to 30% in the percent-
age of patients treated at bedtime across
the quintiles, indicating the association
between bedtime treatment, enhanced
nighttime blood pressure reduction, and
decreased CVD risk. Figure 2 (bottom)
also shows a J-shaped relationship be-
tween achieved daytime clinic SBP and
CVD risk; the adjusted relative CVD risk
was signiﬁcantly higher (P =0.023) in the
ﬁrst than in the second quintile, and then
progressively increased again in the other
three (P = 0.028 between the second and
the last quintile). The percentage of pa-
tients treated with $1 hypertension med-
ication at bedtime was lower (41%) in the
ﬁrst than in the second quintile (57%; P =
0.037).
CONCLUSIONS—This study pro-
spectively investigated in hypertensive
patients with type 2 diabetes the hypoth-
esis that bedtime treatment with $1h y -
pertension medications exerts better
blood pressure control and CVD risk re-
duction than conventional therapy, in
which all medications are ingested upon
waking. The results document, ﬁrst,
greater ambulatory blood pressure con-
trolinpatientsingesting$1hypertension
medications at bedtime than in those in-
gesting all their medications upon awak-
ening. The main differences between
groups in terms of blood pressure control
were achievement in patients treated at
bedtime of 1)s i g n i ﬁcantly lower asleep
blood pressure mean and 2) greater sleep
time relative blood pressure decline, with-
out loss of awake blood pressure lowering
efﬁcacy (Table 2). These administration-
time–dependent effects on sleep time
blood pressure control were strongly as-
sociated with lower CVD risk and in-
creased event-free survival. Indeed, the
progressive reduction in the asleep blood
pressure mean from baselinewas the most
signiﬁcant predictor of survival. More-
over, lack of sleep time blood pressure
control with reference to established
ABPM criteria (18) wasthe most prevalent
factor among subjects with documented
CVD events. As documented in a series of
prospective trials reviewed elsewhere (1),
and also corroborated in the long-term
evaluation provided here, treatment at
bedtime is the most cost-effective and
simplest strategy of successfully achieving
the therapeutic goals of adequate asleep
blood pressure reduction and preserving
or reestablishing the normal 24-h blood
pressure dipping pattern. One could thus
conclude that the increased event-free
survival associated with bedtime chrono-
therapy with $1b l o o dp r e s s u r e –lowering
medications, compared with upon-waking
treatment of all medications, is linked to
better achievement of these novel hyper-
tension therapeutic goals.
Therapeutic intervention in hyper-
tension consists of adequate control of
blood pressure, the goal being to reduce/
avert CVD morbidity and mortality.
Blood pressure control has been deﬁned
Figure 1—Top: Kaplan-Meier survival curves as a function of time of day of hypertension
treatment, i.e., for patients with type 2 diabetes ingesting either all theirblood pressure–lowering
medications upon awakening or $1 medications at bedtime. Bottom: Hazard ratios (95% CIs) of
CVD events (adjusted by age and sex) as a function of time of day of hypertension treatment, i.e.,
for patients with type 2 diabetes ingesting either all their blood pressure–lowering medications
upon awakening or $1 medications at bedtime. Total events include death (from all causes),
cardiovascular events (myocardial infarction, angina pectoris, and coronary revascularization),
cerebrovascular events (stroke and transient ischemic attack), heart failure, and other events
(acute arterial occlusion of lower extremities and thrombotic occlusion of the retinal artery).
Major events include cardiovascular deaths, myocardial infarction, ischemic stroke, and hem-
orrhagic stroke.
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blood pressure level (mainly if not exclu-
sively determined conventionally at the
clinic), without paying attention to po-
tential alterations in the circadian blood
pressure pattern due to treatment. Some
of these studies found that too high a
reduction in clinic blood pressure might
be associated with increased CVD risk,
whereas moderate reduction in blood
pressure would decrease it; such associa-
tion is known as the J-shaped or U-shped
effect (21). We also found a J-shaped as-
sociation in the relation between achieved
clinic blood pressure and CVD risk (Fig. 2,
bottom). However, the relation between
achieved asleep blood pressure mean
and CVD risk (Fig. 2, top)p r e s e n t e da
highly signiﬁcant lower CVD risk associ-
ated with progressive diminished asleep
blood pressure mean. Moreover, the
amount of the asleep blood pressure re-
duction during follow-up was signiﬁ-
cantly correlated with increased number
of patients treated at bedtime. One needs
to realize that 1)m o s tm a r k e t e dm e d i -
ctions do not provide homogeneous
long-lasting efﬁcacy throughout the entire
24 h, 2) no marketed hypertension medi-
cationprovidesgreaterreductionofasleep
than awake blood pressure when admin-
istered in the morning, and 3) increasing
the number of hypertension medications
administered in the morning may lead
to more intensive clinic blood pressure re-
duction but also to a progressive reduction
in the sleep time relative bloodpressure de-
cline toward a more nondipper blood pres-
sure pattern as a consequence of the greater
reduction in awake than asleep blood pres-
sure (1). We thus conclude that the actual
controversy on the possible J-shaped rela-
tion with CVD risk, described so far only
for clinic blood pressure determined in pa-
tients presumably treated in the morning
(21,22), might not apply (when avoiding
nocturnal hypotension) to asleep blood
pressure mean, a more signiﬁcant predictor
ofCVDmorbidityandmortalitythatcanbe
cost-effectively modiﬁed by proper-timed
treatment (1), as also documented here
in patients with type 2 diabetes.
In conclusion, in hypertensive sub-
jectswithtype 2diabetes,werecommend
taking into account the variable of treat-
ment time with respect to the 24-h rest-
activity pattern of each patient. Our
ﬁndings document that a bedtime sched-
ule with $1b l o o dp r e s s u r e –lowering
medications,incomparisonwithaschedule
in which all such medications are ingested
upon awakening, not only improves blood
pressure control and decreases the preva-
lence of nondipping, but it signiﬁcantly
reduces CVD risk. Our results also docu-
ment for the ﬁrst time that reducing the
asleep blood pressure mean while avoid-
ing nocturnal hypotension, a novel thera-
peutic target requiring proper patient
evaluationbyABPM,signiﬁcantlydecreases
CVD morbidity and mortality in patients
with type 2 diabetes.
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